Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PSD | A5PKW4 | 4/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492636 | 0.86 | LTB4R (0.41) | KDM4EADORA1HSD17B10PSDADORA3 | |
| SCHEMBL19206738 | 0.84 | PSD (0.34) | KDM4EGMNNLMNACYP1A2PKM | |
| SCHEMBL19206667 | 0.83 | LTB4R (0.39) | KDM4EHSD17B10PSDADORA3CDC7 | |
| SCHEMBL20543506 | 0.82 | GAA (0.37) | KDM4ELMNAPSDCDC7LTB4R | |
| SCHEMBL19206740 | 0.82 | ADORA2A (0.34) | ADORA2AADORA1PSDADORA3CDC7 | |
| SCHEMBL19206675 | 0.81 | ALDH1A1 (0.35) | KDM4ELMNACYP1A2PSDADORA3 | |
| SCHEMBL19206652 | 0.81 | CDC7 (0.45) | KDM4EHSD17B10PSDADORA3CDC7 | |
| SCHEMBL2680919 | 0.81 | ADORA3 (0.38) | KDM4ELMNAPKMADORA1HSD17B10 | |
| SCHEMBL19206727 | 0.80 | ALDH1A1 (0.45) | KDM4ELMNATSHRHSD17B10ADORA3 | |
| SCHEMBL2680751 | 0.80 | ABCB1 (0.40) | KDM4EADORA2AADORA1HSD17B10ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | claimed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2025-08-19 | — | — | US | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | KDM4E 2418/4885GMNN 1547/4885LMNA 1491/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | KDM4E 3757/4885GMNN 659/4885LMNA 4450/4885 |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KDM4E 4319/4885GMNN 843/4885LMNA 4160/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885GMNN 612/4885LMNA 2946/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | KDM4E 4242/4885GMNN 892/4885LMNA 3816/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885GMNN 612/4885LMNA 2946/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885GMNN 612/4885LMNA 2946/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | KDM4E 3757/4885GMNN 659/4885LMNA 4450/4885 |
| US-10308975-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | KDM4E 4263/4885GMNN 811/4885LMNA 4126/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KDM4E 4319/4885GMNN 843/4885LMNA 4160/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | KDM4E 4304/4885GMNN 849/4885LMNA 4146/4885 |
| US-12391973-B2 | Substituted imidazo[1,2-α]pyrazines as luciferase substrates | PGLS, GLB1, AADAC | KDM4E 4350/4885GMNN 889/4885LMNA 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.